Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of cyclosporine, methylprednisolone, and vincristine is an immunosuppressive regimen that has been used in various medical contexts, particularly for treating certain autoimmune conditions and preventing transplant rejection. ## Pharmacological Components This combination brings together three distinct medications with complementary mechanisms: **Cyclosporine** is a calcineurin inhibitor that suppresses T-lymphocyte activity by blocking the phosphatase activity of calcineurin, thereby decreasing the production of inflammatory cytokines[10]. It's commonly used in organ transplantation and for various autoimmune conditions[6]. **Methylprednisolone** is a corticosteroid with potent anti-inflammatory and immunosuppressive properties. It's used to treat inflammation across multiple organ systems and for various immune-mediated disorders[5]. **Vincristine** is a vinca alkaloid antineoplastic agent that binds to microtubular proteins of the mitotic spindle, leading to cell cycle arrest. It has both antitumor and immunosuppressive effects[3]. ## Clinical Applications The combination therapy of these three medications appears to be used in specific clinical scenarios: 1. **Acute/subacute interstitial pneumonia (A/SIP) in polymyositis/dermatomyositis patients**: A pilot trial used high-dose prednisolone (a corticosteroid similar to methylprednisolone), cyclosporin A, and intravenous pulse cyclophosphamide for this condition, showing some improvement in survival rates[1]. 2. **Immunosuppression in transplantation**: While not explicitly mentioned in the search results for this exact three-drug combination, cyclosporine and corticosteroids like methylprednisolone are cornerstone therapies in transplant medicine[6][8]. 3. **Treatment of certain hematologic malignancies**: Vincristine is commonly used in protocols for acute lymphocytic leukemia, Hodgkin's lymphoma, and other malignancies[3]. ## Drug Interactions There are known interactions between components of this combination: - A moderate drug interaction exists between cyclosporine and methylprednisolone[4], which may require dosage adjustments or careful monitoring. - The immunosuppressive effects of all three medications may be additive, potentially increasing the risk of infection. This combination therapy represents an intensive immunosuppressive approach that would typically be reserved for serious conditions where the benefit outweighs the potential risks of combined immunosuppression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclosporine + methylprednisolone + vincristine.